Pituitary adenylate cyclase-activating polypeptide stimulates renin secretion via activation of PAC1 receptors

Journal of the American Society of Nephrology

Volumn 18, Issue 4, 2007, Pages 1150-1156

  Hautmann, Matthias ^a   Friis, Ulla G ^b   Desch, Michael ^a   Todorov, Vladimir ^a   Castrop, Hayo ^a   Segerer, Florian ^a   Otto, Christiane ^c   Schütz, Günther ^c   Schweda, Frank ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; RAMIPRIL; RENIN;

ANIMAL CELL; ARTICLE; BINDING SITE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; CORONARY BLOOD VESSEL; EXOCYTOSIS; JUXTAGLOMERULAR APPARATUS; KIDNEY BLOOD VESSEL; KIDNEY PERFUSION; KNOCKOUT MOUSE; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; REGULATORY MECHANISM; RENIN RELEASE; WILD TYPE;

EID: 34047238703     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006060633     Document Type: Article

References (30)

1. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH: Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164: 567-574, 1989
2. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H: Pituitary adenylate cyclase-activating polypeptide and its receptors: From structure to functions. Pharmacol Rev 52: 269-324, 2000
3. Sherwood NM, Krueckl SL, McRory JE: The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21: 619-670, 2000
4. Dalsgaard T, Hannibal J, Fahrenkrug J, Larsen CR, Ottesen B: VIP and PACAP display different vasodilatory effects in rabbit coronary and cerebral arteries. Regul Pept 110: 179-188, 2003
5. Whalen EJ, Johnson AK, Lewis SJ: Hemodynamic actions of systemically injected pituitary adenylate cyclase activating polypeptide-27 in the rat. Eur J Pharmacol 365: 205-215, 1999
6. Bruch L, Bychkov R, Kastner A, Bulow T, Ried C, Gollasch M, Baumann G, Luft FC, Haller H: Pituitary adenylate-cyclase-activating peptides relax human coronary arteries by activating K(ATP) and K(Ca) channels in smooth muscle cells. J Vasc Res 34: 11-18, 1997
7. Steenstrup BR, Jorgensen JC, Aim P, Hannibal J, Junge J, Fahrenkrug J, Ottesen B: Pituitary adenylate cyclase activating polypeptide (PACAP): Occurrence and vasodilatory effect in the human uteroplacental unit. Regul Pept 61: 197-204, 1996
8. Warren JB, Wilson AJ, Loi RK, Coughlan ML: Opposing roles of cyclic AMP in the vascular control of edema formation. FASEB J 7: 1394-1400, 1993
9. Warren JB, Donnelly LE, Cullen S, Robertson BE, Ghatei MA, Bloom SR, MacDermot J: Pituitary adenylate cyclase-activating polypeptide: A novel, long-lasting, endothelium-independent vasorelaxant. Eur J Pharmacol 197: 131-134, 1991
10. Minkes RK, McMahon TJ, Hood JS, Murphy WA, Coy DH, McNamara DB, Kadowitz PJ: Differential effects of PACAP and VIP on the pulmonary and hindquarters vascular beds of the cat. J Appl Physiol 72: 1212-1217, 1992
11. Gardiner SM, Rakhit T, Kemp PA, March JE, Bennett T: Regional haemodynamic responses to pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide in conscious rats. Br J Pharmacol 111: 589-597, 1994
12. Arimura A, Li M, Batuman V: Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 107: 661-668, 2006
13. Harmar AJ, Sheward WJ, Morrison CF, Waser B, Gugger M, Reubi JC: Distribution of the VPAC2 receptor in peripheral tissues of the mouse. Endocrinology 145: 1203-1210, 2004
14. Reubi JC: In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann N Y Acad Sci 921: 1-25, 2000
15. Wei Y, Mojsov S: Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: Implications for their role in human physiology. J Neuroendocrinol 8: 811-817, 1996
16. Sreedharan SP, Huang JX, Cheung MC, Goetzl EJ: Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc Natl Acad Sci USA 92: 2939-2943, 1995
17. Lam HC, Takahashi K, Ghatei MA, Kanse SM, Polak JM, Bloom SR: Binding sites of a novel neuropeptide pituitary-adenylate-cyclase-activating polypeptide in the rat brain and lung. Eur J Biochem 193: 725-729, 1990
18. Colwell CS, Michel S, Itri J, Rodriguez W, Tam J, Lelievre V, Hu Z, Waschek JA: Selective deficits in the circadian light response in mice lacking PACAP. Am J Physiol Regul Integr Comp Physiol 287: R1194-R1201, 2004
19. Arimura A, Somogyvari-Vigh A, Miyata A, Mizuno K, Coy DH, Kitada C: Tissue distribution of PACAP as determined by RIA: Highly abundant in the rat brain and testes. Endocrinology 129: 2787-2789, 1991
20. Hackenthal E, Paul M, Ganten D, Taugner R: Morphology, physiology, and molecular biology of renin secretion. Physiol Rev 70: 1067-1116, 1990
21. Otto C, Kovalchuk Y, Wolfer DP, Gass P, Martin M, Zuschratter W, Grone HJ, Kellendonk C, Tronche F, Maldonado R, Lipp HP, Konnerth A, Schutz G: Impairment of mossy fiber long-term potentiation and associative learning in pituitary adenylate cyclase activating polypeptide type I receptor-deficient mice. J Neurosci 21: 5520-5527, 2001
22. Otto C, Hein L, Brede M, Jahns R, Engelhardt S, Grone HJ, Schutz G: Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice. Circulation 110: 3245-3251, 2004
23. Scholz H, Kurtz A: Disparate effects of calcium channel blockers on pressure dependence of renin secretion and flow in the isolated perfused rat kidney. Pflugers Arch 421: 155-162, 1992
24. Schweda F, Wagner C, Kramer BK, Schnermann J, Kurtz A: Preserved macula densa-dependent renin secretion in A1 adenosine receptor knockout mice. Am J Physiol Renal Physiol 284: F770-F777, 2003
25. Friis UG, Jensen BL, Aas JK, Skott O: Direct demonstration of exocytosis and endocytosis in single mouse juxtaglomerular cells. Circ Res 84: 929-936, 1999
26. Friis UG, Jensen BL, Sethi S, Andreasen D, Hansen PB, Skott O: Control of renin secretion from rat juxtaglomerular cells by cAMP-specific phosphodiesterases. Circ Res 90: 996-1003, 2002
27. Della Bruna R, Pinet F, Corvol P, Kurtz A: Calmodulin antagonists stimulate renin secretion and inhibit renin synthesis in vitro. Am J Physiol 262: F397-F402, 1992
28. Lang JA, Yang G, Kern JA, Sigmund CD: Endogenous human renin expression and promoter activity in CALU-6, a pulmonary carcinoma cell line. Hypertension 25: 704-710, 1995
29. Klar J, Vitzthum H, Kurtz A: Aldosterone enhances renin gene expression in juxtaglomerular cells. Am J Physiol Renal Physiol 286: F349-F355, 2004
30. Neher E, Marty A: Discrete changes of cell membrane capacitance observed under conditions of enhanced secretion in bovine adrenal chromaffin cells. Proc Natl Acad Sci U S A 79: 6712-6716, 1982